One of the biggest hurdles of drug development is making sense of vast biological data to predict how drug candidates will behave in living systems. Dublin startup Meta-Flux is tackling this challenge head-on.
Founded in 2020 by biochemist Lee Sherlock, computer scientist Brendan Martin, and Sinah Behsangar, the company has just closed a €1.8 million ($2 million) seed round led by leaders from Pfizer, Merck, Gilead, Google, Amazon, and Indeed.
The team envisions Meta-Flux as an “AI biologist,” an AI system that goes beyond crunching numbers to reason through biological complexity. Sherlock, who brings deep expertise in computational biology and machine learning, explains that many early-stage drug failures stem from the inability to predict how molecules behave in complex biological networks.
“Bringing a new drug to market is slow, expensive, and uncertain. Too often, promising drugs fail because researchers can’t clearly predict how they’ll behave,” said Sherlock.
He added, “A lot of drugs end up failing because they have the wrong application. Our goal isn’t just to get more drugs to market, but to make sure the ones that do actually help the right people. Once you have that drug and once you have the target, we help you figure out what application you should go after, what particular type of disease, what subtype of that disease, and what patients you’re going to be treating.”
Unlike many AI-focused drug discovery companies, including Atomwise, Exscientia, Insilico Medicine, and Isomorphic Labs, that rely primarily on chemistry or black-box models, Meta-Flux integrates data from genes, proteins, and metabolic pathways to build dynamic models of biological systems.
With this new funding, Meta-Flux plans to expand its team of biologists, data engineers, and product developers. Their focus is on forging partnerships across Europe and the U.S., helping pharma companies leverage biology-driven AI to transform preclinical research pipelines.
